David M. Nanus, MD, presented “Standard Treatment for Advanced Prostate Cancer” during the 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.
How to cite: Nanus, David M. “Standard Treatment for Advanced Prostate Cancer” October 3, 2019. Accessed Nov 2024. https://grandroundsinurology.com/standard-treatment-for-advanced-prostate-cancer/
Standard Treatment for Advanced Prostate Cancer – Summary:
David M. Nanus, MD, reviews the approvals for and evidence surrounding therapies to treat advanced prostate cancer. He focuses on taxane chemotherapy, androgen deprivation therapy, androgen receptor pathway inhibitors, bone-targeted therapy, and common approaches in tumor immunotherapy.
About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum designated to informing health care stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Nanus presented this lecture during the 4th iteration of this Summit in 2019.
ABOUT THE AUTHOR
David M. Nanus, MD, is the Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine and the Director of Genitourinary Cancer at New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program. He is also Associate Director of Clinical Services at the Meyer Cancer Center at Weill Cornell.
Dr. Nanus completed his medical training at Albert Einstein College of Medicine in the Bronx. He then went on to complete a Fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center, and completed research training at the Sloan Kettering Institute in Manhattan. He was a physician-scientist at MSKCC and later joined the full-time faculty of Weill Cornell Medicine, where he serves as Chief of the Division of Hematology and Medical Oncology. He serves as PI in clinical, translational, and basic research in genitourinary malignancies and novel targeted therapies, and has 200+ publications. He has received numerous awards, including membership in the American Society for Clinical Investigation and the Association of American Physicians.
